Dossier assessment
Dolutegravir (HIV) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Dolutegravir (HIV) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Dolutegravir (HIV) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Children and adolescents aged 6 to < 18 years who are infected with HIV
Result of dossier assessment:
- Treatment-naive adolescents aged 12 to < 18 years who are infected with HIV: added benefit not proven
- Treatment-experienced adolescents aged 12 to < 18 years who are infected with HIV: added benefit not proven
- Treatment-naive children aged 6 to < 12 year who are infected with HIV-1: added benefit not proven
- Treatment-experienced children aged 6 to < 12 years who are infected with HIV-1: added benefit not proven
Project details
- Project no.
- A22-38
- Commission
- Commission awarded on 01.04.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Dolutegravir (HIV infection in children aged >= 4 weeks to < 6 years) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dolutegravir (HIV infection) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Dolutegravir - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed